Dihydroartemisinin (mixture of α and β isomers)
Selected Variant
HY-W129233-01
Size: 50 mg
Dihydroartemisinin (mixture of α and β isomers) is an anti-malaria and anticancer agent, as well as an active metabolite of artemisinin and its derivatives. Dihydroartemisinin exerts anticancer effects through various molecular mechanisms, such as inhibiting proliferation, inducing apoptosis, inhibiting tumor metastasis and angiogenesis, promoting immune function, inducing autophagy and endoplasmic reticulum stress[1].
Product Specifications
CAS Number
131175-87-6
Product Name Alternative
Dihydroartemisinin (α, β mixture)
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Autophagy; Parasite
Type
Reference compound
Related Pathways
Anti-infection; Apoptosis; Autophagy
Applications
COVID-19-anti-virus
Field of Research
Cancer; Infection
Assay Protocol
https://www.medchemexpress.com/dihydroartemisinin-mixture-of-α-and-β-isomers.html
Purity
98.0
Smiles
C[C@@H]1[C@@]2([H])[C@]34[C@@](OC1O)([H])O[C@](OO3)(CC[C@@]4([H])[C@@H](CC2)C)C
Molecular Formula
C15H24O5
Molecular Weight
284.35
Precautions
H302, H315, H319, H335
References & Citations
[1]Dai X, et al. Dihydroartemisinin: A Potential Natural Anticancer Drug. Int J Biol Sci. 2021 Jan 16;17 (2) :603-622.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Price
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Glypican-3 (1G12), CF740 conjugate, 0.1mg/mL
CD25 / IL2RA (Activated Lymphocyte Marker) (IL2RA/2394), CF405S conjugate, 0.1mg/mL
NKX2.8 (NKX28/2547), CF640R conjugate, 0.1mg/mL
Napsin A (Lung Adenocarcinoma Marker) (NAPSA/1865R), CF488A conjugate, 0.1mg/mL
ERCC1 / RAD10 (Tumor Progression Marker) (ERCC1/2318), CF488A conjugate, 0.1mg/mL
